T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

Bone Marrow Transplantation

Volumn 21, Issue 6, 1998, Pages 543-551

  Barrett, A J ^a   Mavroudis, D ^a   Tisdale, J ^a   Molldrem, J ^a   Clave, E ^a   Dunbar, C ^a   Cottler Fox, M ^b   Phang, S ^a   Carter, C ^b   Okunnieff, P ^b   Young, N S ^a   Read, E J ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chronic myeloid leukemia; Graft versus host disease; Graft versus leukemia; Hematological malignancies; Immune recovery; T cell depleted BMT

Indexed keywords

CYCLOSPORIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0031885659     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701131     Document Type: Article

References (30)

1. Apperley JF, Jones L, Hale G et al. Bone marrow transplantation for chronic myeloid leukaemia: T cell depletion with Campath-1 reduces the incidence of acute graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986; 1: 53-68.
2. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1991; 75: 555-562.
3. Marmont AM, Horowitz MM, Gale RP et al. T cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
4. Butturini A, Gale RP. T-cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant 1988; 3: 185-192.
5. Daley JP, Rozans MK, Smith BR et al. Retarded recovery of functional T cell frequencies in T cell-depleted bone marrow transplants recipients. Blood 1987; 70: 960-964.
6. DeGast GC, Gratama JW, Verdonck LF et al. The influence of T cell depletion on recovery of T cell proliferation to herpesviruses and Candida after allogeneic bone marrow transplantation. Transplantation 1989; 48: 111-115.
7. Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387-393.
8. Barren AJ, Malkovska V. Graft-versus-leukemia: understanding and using the alloimmune response to treat hematological malignancies. Br J Haematol 1996; 93: 754-761.
9. + T lympho-cytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991: 23: 1695-1696.
10. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-ver-sus-host disease. Bone Marrow Transplant 1993; 11: 329.
11. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995; 85: 3302-3312.
12. Sullivan KM, Storb R, Buckner CD el al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. New Engl J Med 1989; 320: 828-834.
13. Naparstek E, Or R, Nagler A et al. T cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
14. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
15. Van Rhee F, Feng L, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: the case for giving donor leucocyte transfusions before the onset of hematological relapse. Blood 1994; 83: 3377-3783.
16. + cell dose predicts survival, post-transplant morbidity and rate of hematological recovery after allogeneic marrow transplants for hématologie malignancies. Blood 1996; 88: 3223-3229.
17. Prentice HG, Gluckman E, Powles R et al for the European Acyclovir for CMV Prophylaxis Study Group. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343: 749-753.
18. Couriel D, Canosa J, Engler H et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18: 347-353.
19. Agarwal R, Doren S, Hicks B, Dunbar CE. Long-term culture of chronic myelogeneous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood 1995; 85: 1306-1312.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Peto R, Peto J. Asymptomatically efficient rank invariant procedures. JR Stat Soc 1972; 135: 185-191.
22. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
23. Mavroudis DA, Jiang YZ, Hensel N et al. Specific depletion of alloreactivity against haplotype mismatched related individuals: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996; 17: 793-799.
24. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17 (Suppl. 3): S5-S6.
25. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996; 17 (Suppl. 3): S1-S3.
26. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukaemia. Blood 1994; 84: 4368-4373.
27. Gratwohl A, Hermans J for the Working Party Chronic Leukaemia of the European Group for Blood and Bone Marrow Transplantation. Allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1996; 17 (Suppl. 3): S7-S9.
28. Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Br J Haeinatol 1996; 92: 251-254.
29. Sutton L, Chastang C, Ribaud P et al for the Société Française de Greffe de Moelle. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study. Blood 1996; 88: 358-365.
30. Frassoni F, Labopin M, Gluckman E et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - a report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13-18.